Lymphoplasmacytic lymphoma and other non-marginal zone lymphomas with plasmacytic differentiation

American Journal of Clinical Pathology

Volumn 136, Issue 2, 2011, Pages 195-210

  Lin, Pei ^a   Molina, Thierry J ^b   Cook, James R ^c   Swerdlow, Steven H ^d  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HÔTEL DIEU   (France)

^c LERNER RESEARCH INSTITUTE   (United States)

^d PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

LPL; Lymphoplasmacytic lymphoma; Plasmacytic differentiation; Society for Hematopathology European Association for Haematopathology Workshop

Indexed keywords

CD23 ANTIGEN; CD5 ANTIGEN; CD79A ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PREDNISONE; RITUXIMAB; TRANSCRIPTION FACTOR PAX5; VINCRISTINE;

ANEMIA; B CELL LYMPHOMA; B LYMPHOCYTE; BLOOD VISCOSITY; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CELL DIFFERENTIATION; CLINICAL FEATURE; CONFERENCE PAPER; CYTOGENETICS; DIFFERENTIAL DIAGNOSIS; HEPATOMEGALY; HEPATOSPLENOMEGALY; HUMAN; IMMUNOPHENOTYPING; LYMPHADENOPATHY; LYMPHOMA; LYMPHOPLASMACYTIC LYMPHOMA; MARGINAL ZONE LYMPHOMA; MORPHOLOGY; NON MARGINAL ZONE LYMPHOMA; PHENOTYPE; PLASMACYTIC DIFFERENTIATION; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPLENOMEGALY;

DIAGNOSIS, DIFFERENTIAL; HUMANS; LYMPHOMA, B-CELL; PLASMA CELLS;

EID: 79961010792     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCP8FOIVTB6LBER     Document Type: Conference Paper

References (61)

1. Molina TJ, Lin P, Swerdlow SH, et al. Mantle zone lymphomas with plasmacytic differentiation and related disorders. Am J Clin Pathol. 2011;136:211-225.
2. Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: IARC Press; 2008:194-195.
3. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. Cancer. 1974;34(suppl):1488-1503.
4. Gerard-Marchant R, Hamlin I, Lennert K, et al. Classification of non-Hodgkin's Lymphomas. Lancet. 1974;2:406-408.
5. Gradowski JF, Jaffe ES, Warnke RA, et al. Follicular lymphomas with plasmacytic differentiation include two subtypes. Mod Pathol. 2010;23:71-79.
6. Fonseca R, Blood EA, Oken MM, et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood. 2002;99:3735-3741. (Pubitemid 34534545)
7. Heerema-McKenney A, Waldron J, Hughes S, et al. Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma. Am J Clin Pathol. 2010;133:265-270.
8. De Vita S, De Re V, Gasparotto D, et al. Oligoclonal non-neoplastic B cell expansion is the key feature of type II mixed cryoglobulinemia: clinical and molecular findings do not support a bone marrow pathologic diagnosis of indolent B cell lymphoma. Arthritis Rheum. 2000;43:94-102. (Pubitemid 30368217)
9. Monteverde A, Sabattini E, Poggi S, et al. Bone marrow findings further support the hypothesis that essential mixed cryoglobulinemia type II is characterized by a monoclonal B-cell proliferation. Leuk Lymphoma. 1995;20:119-124. (Pubitemid 26007438)
10. Quartuccio L, Fabris M, Salvin S, et al. Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis. Rheumatology (Oxford). 2007;46:1657-1661. (Pubitemid 350018486)
11. Leleu X, O'Connor K, Ho AW, et al. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007;82:83-84. (Pubitemid 46033400)
12. The Non-Hodgkin's Lymphoma Classification Project. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood. 1997;89:3909-3918.
13. Garand R, Sahota SS, Avet-Loiseau H, et al. IgG-secreting lymphoplasmacytoid leukaemia: a B-cell disorder with extensively mutated VH genes undergoing Ig isotypeswitching frequently associated with trisomy 12. Br J Haematol. 2000;109:71-80. (Pubitemid 30340581)
14. Morice WG, Chen D, Kurtin PJ, et al. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. Mod Pathol. 2009;22:807-816.
15. Varghese AM, Rawstron AC, Ashcroft AJ, et al. Assessment of bone marrow response in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:53-55.
16. Tournilhac O, Santos DD, Xu L, et al. Mast cells in Waldenström's macroglobulinemia support lymphoplasmacytic cell growth through CD154/CD40 signaling. Ann Oncol. 2006;17:1275-1282. (Pubitemid 44288218)
17. Sargent RL, Cook JR, Aguilera NI, et al. Fluorescence immunophenotypic and interphase cytogenetic characterization of nodal lymphoplasmacytic lymphoma. Am J Surg Pathol. 2008;32:1643-1653.
18. Andriko JAW, Swerdlow SH, Aguilera NI, et al. Is lymphoplasmacytic lymphoma/immunocytoma a distinct entity? a clinicopathologic study of. 20 cases. Am J Surg Pathol. 2001;25:742-751. (Pubitemid 32496863)
19. Natkunam Y, Warnke RA, Zehnder JL, et al. Blastic/blastoid transformation of follicular lymphoma: immunohistologic and molecular analyses of five cases. Am J Surg Pathol. 2000;24:525-534. (Pubitemid 30180745)
20. Lin P, Medeiros LJ. Lymphoplasmacytic lymphoma/ Waldenström macroglobulinemia: an evolving concept. Adv Anat Pathol. 2005;12:246-255. (Pubitemid 41463805)
21. Roberts MJ, Chadburn A, Ma S, et al. Nuclear protein dysregulation in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia [abstract]. Mod Pathol. 2010;23(suppl 1):318A.
22. Gutierrez NC, Ocio EM, de Las Rivas J, et al. Gene expression profiling of B lymphocytes and plasma cells from Waldenström's macroglobulinemia: comparison with expression patterns of the same cell counterparts from chronic lymphocytic leukemia, multiple myeloma and normal individuals. Leukemia. 2007;21:541-549.
23. Chng WJ, Schop R, Price-Troska T, et al. Gene-expression profiling of Waldenström macroglobulinemia reveals a phenotype more similar to chronic lymphocytic leukemia than multiple myeloma. Blood. 2006;108:2755-263.
24. Hatjiharissi E, Ngo H, Leontovich AA, et al. Proteomic analysis of Waldenström macroglobulinemia. Cancer Res. 2007;67:3777-3784.
25. Martin-Jimenez P, Garcia-Sanz R, Balanzategui A, et al. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance. Haematologica. 2007;92:635-642. (Pubitemid 350144265)
26. Kriangkum J, Taylor BJ, Treon SP, et al. Molecular characterization of Waldenström's macroglobulinemia reveals frequent occurrence of two B-cell clones having distinct IgH VDJ sequences. Clin Cancer Res. 2007;13:2005-2013. (Pubitemid 46649866)
27. Kriangkum J, Taylor BJ, Strachan E, et al. Impaired class switch recombination (CSR) in Waldenström macroglobulinemia (WM) despite apparently normal CSR machinery. Blood. 2006;107:2920-2927.
28. Li J, Sze DM, Brown RD, et al. Clonal expansions of cytotoxic T cells exist in the blood of patients with Waldenström macroglobulinemia but exhibit anergic properties and are eliminated by nucleoside analogue therapy. Blood. 2010;115:3580-3588.
29. Cook JR, Aguilera NI, Reshmi-Skarja S, et al. Lack of PAX5 rearrangements in lymphoplasmacytic lymphomas: reassessing the reported association with t(9;14). Hum Pathol. 2004;35:447-454. (Pubitemid 38507081)
30. Kobayashi K, Yokote T, Hirata Y, et al. Two case reports of non-secretory[correction of non-secretary]-Ig types of lymphoplasmacytic lymphoma (LPL) [letter; published online ahead of print January 28, 2010]. Ann Hematol. 2010;89:945- 947. doi:10.1007/s00277-010-0902-8.
31. Terre C, Nguyen-Khac F, Barin C, et al. Trisomy 4, a new chromosomal abnormality in Waldenström's macroglobulinemia: a study of 39 cases. Leukemia. 2006;20:1634-1636. (Pubitemid 44264115)
32. Cook JR, Aguilera NI, Reshmi S, et al. Deletion 6q is not a characteristic marker of nodal lymphoplasmacytic lymphoma. Cancer Genet Cytogenet. 2005;162:85-88. (Pubitemid 41278477)
33. Schop RF, Kuehl WM, Van Wier SA, et al. Waldenström macroglobulinemia neoplastic cells lack immunoglobulin heavy chain locus translocations but have frequent 6q deletions. Blood. 2002;100:2996-3001.
34. Schop RF, Van Wier SA, Xu R, et al. 6q deletion discriminates Waldenström macroglobulinemia from IgM monoclonal gammopathy of undetermined significance. Cancer Genet Cytogenet. 2006;169:150-153. (Pubitemid 44382607)
35. Ocio EM, Schop RF, Gonzalez B, et al. 6q deletion in Waldenström macroglobulinemia is associated with features of adverse prognosis. Br J Haematol. 2007;136:80-86. (Pubitemid 44912591)
36. Chang H, Qi C, Trieu Y, et al. Prognostic relevance of 6q deletion in Waldenström's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma. 2009;9:36-38.
37. Braggio E, Keats JJ, Leleu X, et al. Identification of copy number abnormalities and inactivating mutations in two negative regulators of nuclear factor-kappaB signaling pathways in Waldenström's macroglobulinemia. Cancer Res. 2009;69:3579-3588.
38. Braggio E, Keats JJ, Leleu X, et al. High-resolution genomic analysis in Waldenström's macroglobulinemia identifies disease-specific and common abnormalities with marginal zone lymphomas. Clin Lymphoma Myeloma. 2009;9:39-42.
39. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol. 2006;17:488-494.
40. Fintelmann F, Forghani R, Schaefer PW, et al. Bing-Neel syndrome revisited. Clin Lymphoma Myeloma. 2009;9:104- 106.
41. Kyle RA, Benson J, Larson D, et al. IgM monoclonal gammopathy of undetermined significance and smoldering Waldenström's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:17-18.
42. Sakashita C, Saito T, Kurosu T, et al. Two M-components in a single cell lineage in a patient with a dual isotype secretory B-cell tumour. Br J Haematol. 1998;102:791-794. (Pubitemid 28387064)
43. Buske C, Hoster E, Dreyling M, et al. The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG). Leukemia. 2009;23:153-161.
44. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009;113:4163-4170.
45. Dimopoulos MA, Gertz MA, Kastritis E, et al. Update on treatment recommendations from the Fourth International Workshop on Waldenström's Macroglobulinemia. J Clin Oncol. 2009;27:120-126.
46. Treon SP, Patterson CJ, Kimby E, et al. Advances in the biology and treatment of Waldenström's macroglobulinemia: a report from the 5th International Workshop on Waldenström's Macroglobulinemia, Stockholm, Sweden. Clin Lymphoma Myeloma. 2009;9:10-15.
47. Leleu X, Tamburini J, Roccaro A, et al. Balancing risk versus benefit in the treatment of Waldenström's macroglobulinemia patients with nucleoside analogue-based therapy. Clin Lymphoma Myeloma. 2009;9:71-73.
48. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009;113:3673-3678.
49. Treon SP, Dimopoulos M, Kyle RA. Defining Waldenström's macroglobulinemia. Semin Oncol. 2003;30:107-109.
50. Ameis A, Ko HS, Pruzanski W. M components: a review of 1242 cases. CMAJ. 1976;114:889-892, 895.
51. Lin P, Hao S, Handy BC, et al. Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. Am J Clin Pathol. 2005;123:200-205. (Pubitemid 40194080)
52. Owen RG, Parapia LA, Higginson J, et al. Clinicopathological correlates of IgM paraproteinemias. Clin Lymphoma. 2000;1:39-45.
53. Pangalis GA, Kyrtsonis MC, Kontopidou FN, et al. Differential diagnosis of Waldenström's macroglobulinemia and other B-cell disorders. Clin Lymphoma. 2005;5:235-240. (Pubitemid 40614233)
54. Roberts-Thomson PJ, Nikoloutsopoulos T, Smith AJ. IgM paraproteinaemia: disease associations and laboratory features. Pathology. 2002;34:356-361. (Pubitemid 34827999)
55. Rymkiewicz G, Gos M, Blachnio K, et al. Mantle cell lymphoma presenting with paraproteinemia. Med Oncol. 2005;22:319-323. (Pubitemid 41176328)
56. Yin CC, Lin P, Carney DA, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. Am J Clin Pathol. 2005;123:594-602. (Pubitemid 40418555)
57. Vago JF, Hurtubise PE, Redden-Borowski MM, et al. Follicular center-cell lymphoma with plasmacytic differentiation, monoclonal paraprotein, and peripheral blood involvement: recapitulation of normal B-cell development. Am J Surg Pathol. 1985;9:764-770. (Pubitemid 16215631)
58. Du MQ, Diss TC, Liu H, et al. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. Blood. 2002;100:3415-3418. (Pubitemid 35217095)
59. Bink K, Haralambieva E, Kremer M, et al. Primary extramedullary plasmacytoma: similarities with and differences from multiple myeloma revealed by interphase cytogenetics. Haematologica. 2008;93:623-626. (Pubitemid 351536395)
60. Kremer M, Ott G, Nathrath M, et al. Primary extramedullary plasmacytoma and multiple myeloma: phenotypic differences revealed by immunohistochemical analysis. J Pathol. 2005;205:92-101. (Pubitemid 40029097)
61. Roden AC, Aubry MC, Zhang K, et al. Nodular senile pulmonary amyloidosis: a unique case confirmed by immunohistochemistry, mass spectrometry, and genetic study. Hum Pathol. 2010;41:1040-1045.